Huonslab presents HyDiffuze drug delivery data at US conference

Korean biotech firm Huonslab said Thursday it had presented a preclinical study on its human hyaluronidase platform technology, HyDiffuze, at the annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Denver. The study assessed the applicability of HyDiffuze for monoclonal antibodies and antibody-drug conjugates, or ADCs, to improve subcutaneous drug delivery. Huonslab conducted pharmacokinetic studies using 11 monoclonal antibodies and three ADCs, comparing origina

By The Korea Herald